Trickvalve treatment is a safe alternative developed for high-risk patients over 70 years of age or with an EuroSCORE II value greater than 8%. It is ideal for patients with New York Heart Association (NYHA) Class III-IV symptoms who are at high risk for traditional open-heart surgery.

Patients with the following characteristics are suitable for Trickvalve treatment:

• High-risk patients with multiple comorbidities (at least 2 chronic diseases such as chronic kidney disease, COPD, uncontrolled diabetes)
• Those with an STS score over 8% and porcelain aorta or severe atherosclerotic disease
• Patients over 70 years of age with severe aortic stenosis (valve area < 0.8 cm²)
• Patients requiring a “valve-in-valve” procedure due to bioprosthetic valve degeneration
• Those with a history of chest wall radiation or chest wall deformities

With a 95% successful implantation rate and 92% 5-year survival rate in clinical studies, Trickvalve requires an average 45-minute operation and 2-3 days of hospital stay. The procedure reduces the rate of paravalvular leakage by 60% compared to traditional TAVI, while providing significant improvement in NYHA functional class for 95% of patients.